2024
OncoSexome: the landscape of sex-based differences in oncologic diseases
Shen X, Zhang Y, Li J, Zhou Y, Butensky S, Zhang Y, Cai Z, DeWan A, Khan S, Yan H, Johnson C, Zhu F. OncoSexome: the landscape of sex-based differences in oncologic diseases. Nucleic Acids Research 2024, gkae1003. PMID: 39535034, DOI: 10.1093/nar/gkae1003.Peer-Reviewed Original Research16S rRNA target sequencing of human tumors validates findings of Lachnoclostridium abundance in human melanomas that are heavily CD8+ T-cell infiltrated
Lu L, Johnson C, Khan S, Kluger H. 16S rRNA target sequencing of human tumors validates findings of Lachnoclostridium abundance in human melanomas that are heavily CD8+ T-cell infiltrated. European Journal Of Cancer 2024, 213: 115084. PMID: 39477777, DOI: 10.1016/j.ejca.2024.115084.Peer-Reviewed Original ResearchCharting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification
Jain A, Morris M, Berardi D, Arora T, Domingo-Almenara X, Paty P, Rattray N, Kerekes D, Lu L, Khan S, Johnson C. Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification. Molecular Cancer 2024, 23: 211. PMID: 39342363, PMCID: PMC11438248, DOI: 10.1186/s12943-024-02133-5.Peer-Reviewed Original ResearchConceptsRectal cancerNormal mucosaMetabolite abundancePatient-matched tumorTumor-specific metabolitesMetabolic heterogeneityPatient survivalRectosigmoid colonSigmoid colonAnatomic subsitePatient-matched normal mucosaTransverse colonMetabolomic profilesAscending colonCRC biomarkersMetabolome DatabaseDescending colonMetabolite changesLeft-sidedRight-sidedColorectumRisk factorsMetabolome mapCancerTumorHuman AKR1C3 binds agonists of GPR84 and participates in an expanded polyamine pathway
Dudkina N, Park H, Song D, Jain A, Khan S, Flavell R, Johnson C, Palm N, Crawford J. Human AKR1C3 binds agonists of GPR84 and participates in an expanded polyamine pathway. Cell Chemical Biology 2024 PMID: 39163853, DOI: 10.1016/j.chembiol.2024.07.011.Peer-Reviewed Original ResearchHuman aldo-keto reductase family 1 member C3Mammalian fatty acid synthaseDNA double-strand break responseDouble-strand break responseAldo-keto reductase family 1 member C3Associated with poor prognosisPolyamine pathwayFatty acid synthesisFatty acid synthaseAcid synthaseAKR1C3 activityPoor prognosisBiochemical roleAcid synthesisClinical significanceLigand screeningFerroptosis resistanceDNA damageAKR1C3Metabolic diseasesDiverse cancersDNANADPHAgonists of GPR84GPR84Immunotherapy For US Patients With Metastatic Cancer at the End of Life—Reply
Kerekes D, Khan S. Immunotherapy For US Patients With Metastatic Cancer at the End of Life—Reply. JAMA Oncology 2024, 10: 1134-1134. PMID: 38842840, DOI: 10.1001/jamaoncol.2024.1566.Peer-Reviewed Original ResearchAsparagine synthetase and G‐protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer
Lu L, Zhang Q, Aladelokun O, Berardi D, Shen X, Marin A, Garcia‐Milian R, Roper J, Khan S, Johnson C. Asparagine synthetase and G‐protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer. International Journal Of Cancer 2024, 156: 52-68. PMID: 39039782, PMCID: PMC11537827, DOI: 10.1002/ijc.35104.Peer-Reviewed Original ResearchG protein-coupled estrogen receptor 1KRAS mutant colorectal cancerAsparagine synthetase expressionMutant colorectal cancerColorectal cancerAsparagine synthetaseG-protein coupled estrogen receptor 1 expressionG protein-coupled estrogen receptorWild-typeAssociated with poor overall survivalAdvanced stage tumorsKRAS wild-typeProtective effect of estradiolEffects of estradiolPoor overall survivalEstrogen receptor 1Expression of asparagine synthetasePresence of estradiolIncreased caspase-3 activityDepletion inhibited cell growthColon cancer cohortNutrient supplyAdvanced tumorsOverall survivalStage tumorsAsparagine synthetase and G-protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer
Lu, L, Zhang Q, Shen X, Zhen P, Marin P, Garcia-Milian R, Roper J, Khan S, Johnson C. In press at International Journal of Cancer.Peer-Reviewed Original Research In PressGrowth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex
Aladelokun O, Lu L, Zheng J, Yan H, Jain A, Gibson J, Khan S, Johnson C. Growth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex. Human Genomics 2024, 18: 67. PMID: 38886847, PMCID: PMC11184737, DOI: 10.1186/s40246-024-00635-3.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAspartate-Ammonia LigaseCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorCell ProliferationColorectal NeoplasmsFemaleGene Expression Regulation, NeoplasticHCT116 CellsHeterograftsHumansMaleMiceReceptors, EstrogenReceptors, G-Protein-CoupledSex FactorsXenograft Model Antitumor AssaysConceptsFemale tumor-bearing miceFemale CRC patientsTumor-bearing miceCRC patientsTumor growthInferior survivalAssociated with inferior survivalMetabolic reprogrammingG protein-coupled estrogen receptorTriggering metabolic reprogrammingSustained tumor growthSuppressed tumor growthExpression of asparagine synthetaseCancer cell linesBackgroundSex-related differencesSurvival improvementImpact of sexFemale miceEstrogen receptorCancer growthTranslational relevanceRewiring of metabolic pathwaysCancer burdenMetabolic pathwaysAsparagine synthetaseReasonable expansion of surgical candidates for HCC treatment
Butensky S, Billingsley K, Khan S. Reasonable expansion of surgical candidates for HCC treatment. Clinical Liver Disease 2024, 23: e0153. PMID: 38720794, PMCID: PMC11078523, DOI: 10.1097/cld.0000000000000153.Peer-Reviewed Original ResearchMo1492 EFFECTS OF THE HEALTH INSURANCE MARKETPLACE ON GASTROINTESTINAL CANCER SURGERY OUTCOMES
Butensky S, Kerekes D, Bakkila B, Kurbatov V, Kunstman J, Billingsley K, Khan S. Mo1492 EFFECTS OF THE HEALTH INSURANCE MARKETPLACE ON GASTROINTESTINAL CANCER SURGERY OUTCOMES. Gastroenterology 2024, 166: s-1891. DOI: 10.1016/s0016-5085(24)04833-9.Peer-Reviewed Original ResearchDifferent patient populations: In reply to Higashi, et al.
Khan SA, Kerekes D. JAMA Oncology 2024. 10.1001/jamaoncol.2024.1566.Commentaries, Editorials and LettersDifferent patient populations: In reply to Yorio
Khan SA, Kerekes D. JAMA Oncology 2024. doi: 10.1001/jamaoncol.2023.5932Commentaries, Editorials and LettersDigital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Su D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm D, Khan S, Halaban R, Kluger H, Olino K, Galan A, Clune J. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. Journal For ImmunoTherapy Of Cancer 2024, 12: e008646. PMID: 38519058, PMCID: PMC10961546, DOI: 10.1136/jitc-2023-008646.Peer-Reviewed Original ResearchConceptsCTLA-4 expression levelsCancer-associated fibroblastsAssociated with worse survivalExpression of immune checkpointsLAG-3 expressionDesmoplastic melanomaLymphoid aggregatesCTLA-4PD-1Immune checkpointsIntratumoral leukocytesLAG-3Tumor compartmentsWorse survivalCD20+B cellsIncreased expression of immune checkpointsProgrammed cell death protein 1Macrophage/monocyte markerSentinel lymph node positivityCell death protein 1Associated with poor prognosisLymph node positivityDense fibrous stromaPotential prognostic significanceCore of tumorsImmunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitorsProlonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilagan-Ying Y, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan S, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. Surgical Oncology Insight 2024, 1: 100007. DOI: 10.1016/j.soi.2024.100007.Peer-Reviewed Original ResearchFactors associated with early mortalityCases of pancreatic adenocarcinomaPancreatic adenocarcinoma resectionRisk of early mortalityLength of stayEarly mortalityAdjuvant chemotherapyPancreatic adenocarcinomaChemotherapy utilizationAdenocarcinoma resectionRisk factors associated with early mortalityOmission of adjuvant therapyNon-metastatic pancreatic adenocarcinomaMultivariate Cox regression modelAssociated with early mortalityPost-resection survivalIncreased risk of early mortalityParticipant Use FileProlonged hospital stayProlonged length of stayAdjuvant chemotherapy utilizationDecrease perioperative complicationsCox regression modelsNon-academic centersHospital risk factorsImmunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatmentDigital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Su D, Schoenfeld D, Wael I, Cabrejo R, Baumann R, Rimm D, Khan SA, Halaban R, Kluger H, Olino K, Galan A, Clune J, Kluger H, Clune J. Journal of ImmunoTherapy of Cancer 2024.12(3), e008646. https://doi.org/10.1136/jitc-2023-008646Peer-Reviewed Original ResearchCell surface RNAs control neutrophil recruitment
Zhang N, Tang W, Torres L, Wang X, Ajaj Y, Zhu L, Luan Y, Zhou H, Wang Y, Zhang D, Kurbatov V, Khan S, Kumar P, Hidalgo A, Wu D, Lu J. Cell surface RNAs control neutrophil recruitment. Cell 2024, 187: 846-860.e17. PMID: 38262409, PMCID: PMC10922858, DOI: 10.1016/j.cell.2023.12.033.Peer-Reviewed Original ResearchConceptsCell surfaceMammalian homologOuter cell surfaceRNA transportGlycan modificationsMammalian cellsSID-1Cellular functionsRecruitment to inflammatory sitesGlycoRNARNAMurine neutrophilsFunctional significanceNeutrophil recruitmentNeutrophil recruitment to inflammatory sitesBiological importanceCellsNeutrophil adhesionReduced neutrophil adhesionHomologyGlycansGenesInflammatory sitesRecruitmentEndothelial cellsPhase II Study of Peri-operative Modified FOLFIRINOX in Localized Pancreatic Ductal Adenocarcinoma
Cecchini M, Salem R, Robert M, Czerniak S, Rajaei M, Townsend J, Blaha O, Zelterman D, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan SA, Cha C, Billingsley K, Kunstman J, Chowdhury S, Tseng R, Mauricio C, Yugawa D, Escobar-Hoyos L, Johung K, Wiess C, Spickard C, Aushev V, Laliotis G, Jurdi A, Liu M, Lacy JA. Phase II Study of Peri-operative Modified FOLFIRINOX in Localized Pancreatic Ductal Adenocarcinoma. In press at JAMA Oncology 2024.Peer-Reviewed Original Research In PressProlonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilaga-Ying, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan SA, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. In press at Surgical Oncology Insight 2024.Peer-Reviewed Original Research In Press